Adial Pharmaceuticals, Inc. Proceeds from Sale of Equity Method Investments
Adial Pharmaceuticals, Inc. (ADIL) reported Proceeds from Sale of Equity Method Investments of $0 for the 6-month period ending 2025-03-31, per its 10-Q filed 2025-08-13.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfEquityMethodInvestments · last filed 2026-03-05
- 2025-03-31: Proceeds from Sale of Equity Method Investments 6 month $0.00.
- 2023-06-30: Proceeds from Sale of Equity Method Investments $4.00M.
| Period end | Proceeds from Sale of Equity Method Investments | Proceeds from Sale of Equity Method Investments 6 month |
|---|---|---|
| 2025-03-31 | $0.00 10-Q · filed 2025-08-13 | |
| 2023-06-30 | $4.00M 10-K · filed 2026-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| BIOVIE INC. (BIVI) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |